Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts

Baquero, Maria T; Lostritto, Karen; Gustavson, Mark D; Bassi, Kimberly A; Appia, Franck; Camp, Robert L; Molinaro, Annette M; Harris, Lyndsay N; Rimm, David L

doi:10.1186/bcr2937

Breast Cancer Research

Table 6 Univariate analysis of tumor and clinical risk factors for progression-free survival in TAX 307S

From: Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts

	TAX 307S cohort
Variable	No. of patients (n = 140)	HR	95% CI	P*
Age	108 (77.1)	0.977	0.955-1.00	0.060
Other	10 (7.1)
Unknown	22 (15.7)
Menopausal status
Premenopausal	29 (20.7)	1.000		0.083
Postmenopausal	79 (56.4)	0.627	0.375-1.046
Other	10 (7.1)
Unknown	22 (15.7)
Tumor size (cm)
≤ 2	24(17.1)	1.000		0.580
2-5	56 (40.0)	0.728	0.567-1.136
≥ 5	22 (15.8)	1.134	0.641-2.142
Other	15 (10.7)
Unknown	23 (16.4)
Nodal status
Negative for node metastasis	33 (23.6)	1.000		0.119
Positive for node metastasis	62 (44.3)	0.993	0.595-1.249
Other	23 (16.4)
Unknown	22 (15.7)
Tumor grade
Well/moderately differentiated	31 (22.1)	1.000		0.163
Poorly/undifferentiated	59 (42.1)	1.412	0.758-1.904
Other	28 (20.1)
Unknown	22 (15.7)
ER status
ER negative	40 (28.6)	1.000		0.236
ER positive	50 (35.7)	0.750	0.465-1.208
Other	28 (20.0)
Unknown	22 (15.7)
PR status
PR negative	41 (29.3)	1.000		0.847
PR positive	46 (32.9)	0.954	0.592-1.538
Other	31 (22.1)
Unknown	22 (15.7)
Prior adjuvant chemotherapy
No therapy	55 (39.3)	1.000		0.983
Yes therapy	53 (37.9)	1.005	0.656-1.538
Other	10 (7.1)
Unknown	22 (15.7)
Prior adjuvant hormonal therapy
No therapy	71 (50.7)	1.000		0.512
Yes therapy	37 (26.4)	0.859	0.549-1.349
Other	10 (7.1)
Unknown	22 (15.7)
Prior metastatic hormonal therapy
No therapy	80 (57.1)	1.000		0.176
Yes therapy	28 (20.0)	0.711	0.434-1.165
Other	10 (7.1)
Unknown	22 (15.7)
Response to therapy
Responder	56 (40.0)	1.000	1.404-3.488	0.0006
Non-responder	45 (32.2)	2.213
Other	17 (12.1)
Unknown	22 (15.7)
Treatment
FAC¹	54 (38.6)	1.000		0.315
TAC²	54 (38.6)	1.256	0.805-1.960
Other	10 (7.1)
Unknown	22 (15.7)
MAP-tau expression
MAP-tau low expression	73 (52.1)	1.000		0.011
MAP-tau high expression	35 (25.0)	0.538	0.333-0.871
Other	10 (7.1)
Unknown	22 (15.7)

* P is given for Cox multivariate analysis, statistically significant P values (P < 0.05) are in bold, trending P values are in italics;
¹FAC, 5-fluorouracil-doxorubicin-cyclophosphamide combination
²TAC, docetaxel-doxorubicin- cyclophosphamide combination
CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com